Accordingly, JHU083 treatment in vivo in mouse models of melanoma combined with either ACT or anti-PD-1 antibody exhibited significant expansion of TIL numbers, resulting in improved tumour control and prolonged survival when compared to either agent alone [330]. The gene discussed is PDCD1; the disease is neoplasm.